![David Baltimore](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Baltimore
Directeur/Membre du Conseil chez REGULUS THERAPEUTICS INC.
Fortune : 4 568 $ au 30/06/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Louis Breton | M | - |
Calimmune, Inc.
![]() Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | 18 ans |
Jeffrey Wiezorek | M | 52 |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 13 ans |
Jeenjoo Kang | M | 40 |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Lili Yang | M | - |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Margo Roberts | M | 69 |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 2 ans |
James P. Sullivan | M | - |
Calimmune, Inc.
![]() Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | 9 ans |
Edmund Kim | M | - |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Pin Wang | M | - |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
James Rickey | M | 45 | 6 ans | |
David Szekeres | M | 50 | 1 ans | |
Paul Grint | M | 66 | 3 ans | |
Bruce Carter | M | 80 | 15 ans | |
Pamela Wapnick | F | 58 | 9 ans | |
Daniel Chevallard | M | 44 | 7 ans | |
Madhavan Balachandran | M | 73 | 20 ans | |
David W. Beier | M | 75 | 10 ans | |
Michael Kelly | M | 67 | 14 ans | |
Roger McCarthy | M | 75 |
Massachusetts Institute of Technology
| 5 ans |
Thomas Kurfess | M | - |
Massachusetts Institute of Technology
| 3 ans |
Lisa McIlrath | M | - |
Massachusetts Institute of Technology
| 8 ans |
Barbara Poggiali | M | 61 |
Massachusetts Institute of Technology
| 5 ans |
Reza Abhari | M | 62 |
Massachusetts Institute of Technology
| 3 ans |
Stefano Bertozzi | M | - |
Massachusetts Institute of Technology
| 10 ans |
Vasant Prakash Gandhi | M | - | 5 ans | |
Tom A. Stefanick | M | - |
Massachusetts Institute of Technology
| 5 ans |
Mark Gus Alexandridis | M | 66 |
Massachusetts Institute of Technology
| 6 ans |
Harry Atwater | M | - |
Massachusetts Institute of Technology
| 10 ans |
Chan Yoo | M | 59 |
Massachusetts Institute of Technology
| 8 ans |
Michael Severino | M | 58 | 10 ans | |
Steve Brown | M | - |
Massachusetts Institute of Technology
| 5 ans |
Steven Webster | M | 67 |
Massachusetts Institute of Technology
| 5 ans |
John Moriarty | M | 56 | 6 ans | |
Steve Woolfson | M | - |
Massachusetts Institute of Technology
| 6 ans |
Diana McKenzie | F | 59 | 12 ans | |
Craig Shepherd | M | - | 7 ans | |
Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 ans |
Craig Griffin | M | - |
Massachusetts Institute of Technology
| 5 ans |
Joseph Newell | M | 54 | 7 ans | |
Rachel Lenington | F | 51 | 10 ans | |
Nathan Hardy | M | 48 | 10 ans | |
Richard Williams | M | 55 | 5 ans | |
Eliot Charles | M | 62 |
Massachusetts Institute of Technology
| 10 ans |
Svetlana Lucas | M | 52 |
California Institute of Technology
![]() California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | 5 ans |
Erin Lavelle | F | 46 | 15 ans | |
Ramez Elgammal | M | - |
California Institute of Technology
![]() California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | 4 ans |
Sam Pfister | M | - |
California Institute of Technology
![]() California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | 6 ans |
Hongming Chen | M | 53 |
Massachusetts Institute of Technology
| 3 ans |
Robert Azelby | M | 56 | 5 ans | |
Laurie Stelzer | F | 56 | 2 ans | |
Yi Ning Zhao | M | 53 | 9 ans | |
Marco Renoldi | M | 67 | 3 ans | |
Warren Chou | M | - |
Massachusetts Institute of Technology
| 6 ans |
David Chang | M | 64 |
Massachusetts Institute of Technology
| 13 ans |
Thomas Zindrick | M | 65 | 8 ans | |
Morris Kesler | M | - |
Massachusetts Institute of Technology
| 5 ans |
James Daly | M | 62 | 9 ans | |
J. Wargo | M | 69 |
Massachusetts Institute of Technology
| 6 ans |
Guo Zhong Xie | M | 64 |
Massachusetts Institute of Technology
| 4 ans |
Ethan E. Jacks | M | 70 |
Massachusetts Institute of Technology
| 5 ans |
Mark A. Clements | M | - |
Massachusetts Institute of Technology
| 3 ans |
Douglas Williams | M | 66 | 7 ans | |
Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 ans |
George Economou | M | 71 |
Massachusetts Institute of Technology
| 5 ans |
Adnan Akant | M | - |
Massachusetts Institute of Technology
| 5 ans |
Mike McElroy | M | - |
Massachusetts Institute of Technology
| 9 ans |
Bob Goodof | M | - |
Massachusetts Institute of Technology
| 5 ans |
Joe Schirripa | M | - |
Massachusetts Institute of Technology
| 6 ans |
J. Reason | M | 83 | 12 ans | |
Brian Daniels | M | 65 |
Massachusetts Institute of Technology
| 4 ans |
Anders Hove | M | 58 | 8 ans | |
Anna Richo | F | 63 | 9 ans | |
Frederick Gluck | M | 88 | 13 ans | |
Vance D. Coffman | M | 79 | 9 ans | |
Dominique Monnet | M | 65 | 11 ans | |
Jon Kayyem | M | 60 |
Calimmune, Inc.
![]() Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | 11 ans |
Mark Foletta | M | 63 | 5 ans | |
Timothy Martin | M | 55 | 3 ans | |
Adrianna Ma | F | 50 |
Massachusetts Institute of Technology
| 5 ans |
Ayman Mahmoud Hindy | M | - |
Massachusetts Institute of Technology
| 4 ans |
Mostafa Terrab | M | 68 |
Massachusetts Institute of Technology
| 5 ans |
Jin Long Chen | M | 61 | 4 ans | |
George Morrow | M | 72 | 10 ans | |
Eran Egozy | M | - |
Massachusetts Institute of Technology
| 4 ans |
William P. Sheridan | M | 69 | 5 ans | |
Cynthia Flowers | F | 64 | 5 ans | |
Javier de Luis | M | - |
Massachusetts Institute of Technology
| 8 ans |
Emanuel M. Sachs | M | - |
Massachusetts Institute of Technology
| 8 ans |
Beth A. Marcus | M | - |
Massachusetts Institute of Technology
| 5 ans |
François de Carbonnel | M | 78 | 10 ans | |
Warren Chen | M | - |
Massachusetts Institute of Technology
| 4 ans |
Ford Tamer | M | 62 |
Massachusetts Institute of Technology
| 5 ans |
Catherine Corrigan | M | 55 |
Massachusetts Institute of Technology
| 5 ans |
John Smither | M | 71 | 6 ans | |
Thomas Johannes W. Dittrich | M | 60 | 4 ans | |
Thomas H. Lee | M | 64 |
Massachusetts Institute of Technology
| 6 ans |
Subodh Kulkarni | M | 59 |
Massachusetts Institute of Technology
| 4 ans |
Suresh Thirugnanam | M | 60 |
Massachusetts Institute of Technology
| 4 ans |
Albert Wong | M | 61 |
Massachusetts Institute of Technology
| 3 ans |
Simos Simeonidis | M | 54 | 3 ans | |
Allison Wey | F | - | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 99 | 99,00% |
Suisse | 1 | 1,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- David Baltimore
- Réseau Personnel